Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Tapan Mahendra KadiaPatrick K RevilleXuemei WangCaitlin R RauschGautam BorthakurNaveen PemmarajuNaval G DaverCourtney D DiNardoKoiji SasakiGhayas C IssaMaro Ohanian DOGuillermo Montalban-BravoNicholas James ShortNitin JainAlessandra FerrajoliKapil N BhallaElias J JabbourKoichi TakahashiRashmi MallaKelly QuagliatoRashmi Kanagal-ShamanaSairah A AhmedMichael AndreeffGuillermo Garcia ManeroMarina Y KonoplevaFarhad RavandiHagop M KantarjianPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA is an effective regimen among older or unfit patients with newly diagnosed AML. The rates of overall survival and DFS are encouraging. Further study of this non-anthracycline-containing backbone in younger patients, unfit for intensive chemotherapy, as well as comparisons to standard frontline therapies is warranted.